{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T04:15:52Z","timestamp":1684556152852},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2011,3,15]],"date-time":"2011-03-15T00:00:00Z","timestamp":1300147200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1038\/nrclinonc.2011.35","type":"journal-article","created":{"date-parts":[[2011,3,15]],"date-time":"2011-03-15T13:40:22Z","timestamp":1300196422000},"page":"257-258","source":"Crossref","is-referenced-by-count":1,"title":["Rituximab for follicular lymphoma: maintaining an open mind"],"prefix":"10.1038","volume":"8","author":[{"given":"Bruce D.","family":"Cheson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,3,15]]},"reference":[{"issue":"Suppl. 15","key":"BFnrclinonc201135_CR1","doi-asserted-by":"publisher","first-page":"a8100","DOI":"10.1200\/jco.2010.28.15_suppl.8100","volume":"28","author":"C Flowers","year":"2010","unstructured":"Flowers, C. et al. Use of maintenance rituximab (R) in the United States following R-based induction for follicular lymphoma (FL) [abstract]. J. Clin. Oncol. 28 (Suppl. 15), a8100 (2010).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201135_CR2","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","volume":"377","author":"G Salles","year":"2011","unstructured":"Salles, G. et al. Rituximab manitenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 377, 42\u201351 (2011).","journal-title":"Lancet"},{"key":"BFnrclinonc201135_CR3","doi-asserted-by":"publisher","first-page":"4480","DOI":"10.1200\/JCO.2010.28.4786","volume":"28","author":"G Martinelli","year":"2010","unstructured":"Martinelli, G. et al. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35\/98. J. Clin. Oncol. 28, 4480\u20134484 (2010).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201135_CR4","doi-asserted-by":"crossref","first-page":"a6","DOI":"10.1182\/blood.V116.21.6.6","volume":"116","author":"KM Ardeshna","year":"2010","unstructured":"Ardeshna, K. M. et al. An intergroup randomised trial of rituximab versus a watch and wait strategy in patients with stage II, III, IV asymptomatic, non-bulky follicular lymphoma (grades 1, 2 and 3a). A preliminary analysis [abstract]. Blood 116, a6 (2010).","journal-title":"Blood"},{"key":"BFnrclinonc201135_CR5","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1200\/JCO.2008.17.1561","volume":"27","author":"H Hochster","year":"2009","unstructured":"Hochster, H. et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progession-free survival in advanced indolent lymphoma: Results of the randomized phase III ECOG1496 study. J. Clin. Oncol. 27, 1607\u20131614 (2009).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201135_CR6","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1200\/JCO.2009.26.5827","volume":"28","author":"MH van Oers","year":"2010","unstructured":"van Oers, M. H. et al. Rituximab maintenance treatment of relapsed\/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J. Clin. Oncol. 28, 2853\u20132858 (2010).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201135_CR7","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1200\/JCO.2005.12.191","volume":"23","author":"JD Hainsworth","year":"2005","unstructured":"Hainsworth, J. D. et al. Maximizing therapeutic benefit of rituximab: maintenance therapy versus retreatment at progression in patients with indolent non-Hodgkin's lymphoma\u2014a randomized phase II trial of the Minnie Pearl Cancer Research Network. J. Clin. Oncol. 23, 1088\u20131095 (2005).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201135_CR8","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","volume":"108","author":"MH van Oers","year":"2006","unstructured":"van Oers, M. H. et al. Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin's lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 108, 3295\u20133301 (2006).","journal-title":"Blood"},{"key":"BFnrclinonc201135_CR9","doi-asserted-by":"publisher","first-page":"4003","DOI":"10.1182\/blood-2006-04-016725","volume":"108","author":"R Forstpointner","year":"2006","unstructured":"Forstpointner, R. et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 108, 4003\u20134008 (2006).","journal-title":"Blood"},{"key":"BFnrclinonc201135_CR10","doi-asserted-by":"crossref","first-page":"436s","DOI":"10.1200\/jco.2009.27.15_suppl.8509","volume":"27","author":"C Gisselbrecht","year":"2009","unstructured":"Gisselbrecht, C. et al. R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by autologous stem cell transplantation: CORAL study [abstract 8509]. J. Clin. Oncol. 27, 436s (2009).","journal-title":"J. Clin. Oncol."}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2011.35.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2011.35","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2011.35.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T03:18:50Z","timestamp":1684466330000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrclinonc.2011.35"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,15]]},"references-count":10,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["BFnrclinonc201135"],"URL":"https:\/\/doi.org\/10.1038\/nrclinonc.2011.35","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3,15]]}}}